Form 4 for LGND LIGAND PHARMACEUTICALS INC

Accepted 2026-06-12 17:27:26 ET · period of report 2026-06-05 · accession 0002001011-26-000103 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-06-12 17:27	2026-06-05	LGND	Aryeh Jason	Dir	A - Grant	$0.00	+836	107.6K	+0.8%	$0
DM	2026-06-12 17:27	2026-06-10+	LGND	Aryeh Jason	Dir	S - Sale	$250.00	-5,000	102.6K	-5%	-$1.25M
D	2026-06-12 17:27	2026-06-05	LGND	Aryeh Jason	Dir	A - Grant	$0.00	+2,938	2,938	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-06-05	A	A	836	$0.00	107,580	D	—	—	(F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. (F2) The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records.
2	Common	Common Stock	2026-06-10	S	D	500	$250.00	107,080	D	—	—
3	Common	Common Stock	2026-06-11	S	D	4,500	$250.00	102,580	D	—	—
4	Derivative	Non-Qualified Stock Option (right to buy)	2026-06-05	A	A	2,938	$0.00	2,938	D	$237.00 · — to 2036-06-05	2,938 Common Stock	(F4) Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.